In this Review, we discuss the role of bispecific antibodies in patients with cancer, including history and development, as well as innovative targeting strategies, clinical applications, and adverse events. We
Currently, ERY974, a humanized IgG4 bispecific T cell-redirecting antibody recognizing glypican-3 and CD3, is in phase I clinical trials. After a first-in-human clinical trial of an anti-CD28 agonist monoclonal antibody resulting in severe life-threatening adverse events, the minimal anticipated ...
Phase I clinical trial of the bispecific antibody MDX-H210 (anti-Fc gamma RI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer. Br J Cancer. 2003; 89 :2234–2243. doi: 10.1038/sj.bjc.6601367. [ Cross Ref ]...
What is important to know before starting bispecific antibody treatment? Something that's important for patients to know is that although this is not your typical chemotherapy—you're not going to see that hair loss, or maybe the [gastrointestinal] side effects, or some of the things that ...
American Society of Clinical Oncology bsAb: Bispecific antibody CMR: Complete metabolic response CR: Complete response CRS: Cytokine release syndrome DLBCL: Diffuse large B-cell lymphoma Epcor: Epcoritamab FL: Follicular lymphoma Glofit: Glofitamab ICANS: Immune effector cell‐associated ...
Antibody fragment therapy Antibodies Antibody therapy Acta Pharm. Sin. B13, 3583–3597 (2023). ArticleCASPubMedPubMed CentralGoogle Scholar Elshiaty, M., Schindler, H. & Christopoulos, P. Principles and current clinical landscape of multispecific antibodies against cancer.Int. J. Mol. Sci.22, ...
(with the IgG portion) and LTβR with the scFv. This TRAIL-R2-LTβR bispecific antibody, as well as another form in which the anti-LTβR scFv was fused to the N-terminus of the heavy chain, demonstrated good pharmacokinetics, stability, and pre-clinical efficacy (Michaelson et al., ...
checkpoint while also inhibiting the production of new blood vessels (angiogenesis). LM-299 has a differentiated molecular design, comprising an anti-VEGF antibody linked to two C-terminal single domain anti-PD-1 antibodies. A Phase 1 clinical trial for...
Combination strategyAntibodyTargetPhaseClinical trialAdaptive symptomSource of information Antibody potency IGM2323, 1 + 10 CD3/CD20 I/II NCT04082936 Non-Hodgkin lymphoma, follicular lymphoma, DLBCL https://www.clinicaltrials.gov/ Glofitamab, 2 + 1 CD3/CD20 Marketing – DLBCL 2023, FDA Trispecific...
Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial. Gynecol Oncol. 2022;166:S47–S48. Article Google Scholar Gandhi L, Rodriguez-Abreu D...